{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:09:18Z","timestamp":1789711758426,"version":"4.0.1"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017958","name":"Health Commission of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017958","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Paediatric generalised pustular psoriasis (GPP) is rare, frequently relapsing and associated with limited evidence for targeted therapy. Vunakizumab is an anti-interleukin-17A monoclonal antibody, but data in paediatric GPP are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed three boys with recurrent GPP who received short-course vunakizumab during acute flares. Clinical characteristics, diagnostic details, treatment timelines, follow-up outcomes and Generalized Pustular Psoriasis Area and Severity Index (GPPASI) scores were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A 13-year-old boy (87.5\u00a0kg) with ciclosporin-dependent recurrent GPP received vunakizumab 240 mg at weeks 0 and 2 with concomitant topical therapy; GPPASI decreased from 18 to 1, and no relapse was documented during approximately 6 months of follow-up. An 8-year-old boy (35\u00a0kg) received a single 120-mg administration; GPPASI decreased from 11 to 2, and no recurrent pustular eruption was reported during approximately 15 months of available follow-up, which was predominantly remote after the initial visit. Another 8-year-old boy (32\u00a0kg) with a febrile flare received two 120-mg administrations; GPPASI decreased from 14 to 2, and no relapse was documented during approximately 3 months of follow-up. No adverse events considered treatment-related were documented during the available observation periods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Short-course vunakizumab was temporally associated with rapid clinical improvement in three paediatric patients with acute GPP flares. Larger prospective studies with standardised follow-up are needed to evaluate efficacy, paediatric dosing, relapse prevention and long-term safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1890409","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:38:59Z","timestamp":1789709939000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Short-course vunakizumab associated with rapid improvement of acute flares in paediatric generalised pustular psoriasis: a three-patient case series"],"prefix":"10.3389","volume":"17","author":[{"given":"Juan","family":"Huang","sequence":"first","affiliation":[{"name":"Hubei University of Chinese Medicine","place":["Wuhan, China"]},{"name":"Department of Dermatology, Traditional Chinese and Western Medicine Hospital of Wuhan, Hubei University of Chinese Medicine","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[{"name":"Hubei University of Chinese Medicine","place":["Wuhan, China"]},{"name":"Department of Dermatology, Traditional Chinese and Western Medicine Hospital of Wuhan, Hubei University of Chinese Medicine","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqian","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wuhan No.1 Hospital","place":["Wuhan, China"]},{"name":"Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Traditional Chinese and Western Medicine Hospital of Wuhan, Hubei University of Chinese Medicine","place":["Wuhan, China"]},{"name":"Department of Dermatology, Wuhan No.1 Hospital","place":["Wuhan, China"]},{"name":"Hubei Province Key Laboratory of Skin Infection and Immunity","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province Academy of Traditional Chinese Medicine","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Chen","sequence":"additional","affiliation":[{"name":"Hubei University of Chinese Medicine","place":["Wuhan, China"]},{"name":"Department of Dermatology, Traditional Chinese and Western Medicine Hospital of Wuhan, Hubei University of Chinese Medicine","place":["Wuhan, China"]},{"name":"Department of Dermatology, Wuhan No.1 Hospital","place":["Wuhan, China"]},{"name":"Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Province Key Laboratory of Skin Infection and Immunity","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1648209","article-title":"An update on generalized pustular psoriasis","volume":"15","author":"Gooderham","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ped4.12395","article-title":"The update of treatment strategies in pediatrics with generalized pustular psoriasis in China","volume":"7","author":"Chen","year":"2023","journal-title":"Pediatr Investig"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1292941","article-title":"The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab","volume":"14","author":"Hawkes","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.01.019","article-title":"IL-36 and IL-17A cooperatively induce a psoriasis-like gene expression response in human keratinocytes","volume":"141","author":"Miura","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.031","article-title":"Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"92","author":"Yan","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2560505","article-title":"Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis across different regions of China: a post-hoc exploratory analysis of a phase III randomized controlled trial","volume":"36","author":"Zhu","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/BTT.S592069","article-title":"Vunakizumab and acitretin for elderly refractory generalized pustular psoriasis: a case report and comprehensive literature review","volume":"20","author":"Deng","year":"2026","journal-title":"Biologics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40257-021-00653-0","article-title":"Clinical disease measures in generalized pustular psoriasis","volume":"23","author":"Burden","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1899111","article-title":"Successful treatment of paediatric generalized pustular psoriasis with secukinumab: a case series","volume":"33","author":"Albela","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1159\/000526037","article-title":"Severe generalized pustular psoriasis successfully treated with ixekizumab: a case report","volume":"14","author":"Burlando","year":"2022","journal-title":"Case Rep Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1890409\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:39:00Z","timestamp":1789709940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1890409\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2026.1890409"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1890409","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1890409"}}